All GLG News Analyses Filed Under: Endocrinology

Dapagliflozin has a long way to go to prove its efficacy and safety as a potential diabetes medication. However, innovative medications are welcome as they will be pieces of the diabetic solution puzzle.

Given that obesity is one of the prime causes of type II diabetes, and that an important part of the patient's treatment should be directed to weight loss which improves insulin resistance, I feel that prescribing drugs that you know will cause the patient to fail at losing weight are counterproductive. ...

This article cited a comprehensive review from the Agency for Healthcare Research and Quality.  The paper from AHRQ reviewed a litany of available clinical evidence on 10 commonly used medications for the treatment of diabetes.  The investigators looked at a variety...

Important study. Cost is certainly a significant side-effect so it is good to have the documentation that less expensive options may provide adequate effectiveness for most patients. However, it is all relative.  For any particular individual, certain classes of drugs may provide greater benefit...

SIRTRIS is one of the leading "sites" worldwide on this field. They have profound knowledge about the human sirtuin gene family.

Galvus does not seem to have a competitive edge over Januvia, its main competition. Galvus needs to demonstrate a yet unknown significant advantage to gain significant market share.

Resveritrol is the new "in" compound. It may indeed have some of the effects shown biochemically. Certain foods contain it, but not in enough quantity(at least that may be why we do not see the effects tauted). Only furher studies on the compound will show if it will have any merit.

- the incidence of diabetes is the U.S.A. is increasing - many new drugs are being introduced, and competition is fierce - this study shows new drugs no better than older drugs

To answer the client question in a word: no.

Long-term comparisons of glycemic control are lacking between newer and older diabetes medications. However this is a one-dimensional comparison. Newer medications have significant other advantages over the older medications, but both are needed to safely reach glycemic goals.